Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Παρόμοια τεκμήρια

• Potential applications of Bruton’s tyrosine kinase inhibitors for the prevention of allergic reactions
  ανά: Dispenza, Melanie C., κ.ά.
  Έκδοση: (2017)
• Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy
  ανά: Dispenza, Melanie C., κ.ά.
  Έκδοση: (2018)
• The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
  ανά: Dispenza, Melanie C.
  Έκδοση: (2021)
• Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
  ανά: Woyach, Jennifer A., κ.ά.
  Έκδοση: (2014)
• Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
  ανά: Noy, Ariela, κ.ά.
  Έκδοση: (2017)